PROJECT

Projects

Summary of Investment Information

Project Number

44289

Company Name

GLENMARK PHARMACEUTICALS LIMITED

Date SPI Disclosed

Mar 30, 2021

Country

India

Region

South Asia

Projected Board Date

Jul 9, 2020

Environmental Category

B - Limited

Status

Completed

Last Updated Date

Oct 19, 2024

Department

Regional Industry - MAS Asia & Pac

Industry

other

Previous Events

Approved : Jul 9, 2020
Signed : Feb 12, 2021
Invested : Apr 15, 2021

Sector

other

Project Description

Glenmark Pharmaceuticals Limited (“Glenmark” or “the Company”) is a global research-led pharmaceutical company with presence across generics, specialty, and OTC business with global presence in over 80 countries. Glenmark’s key therapy focus areas are respiratory, dermatology and oncology. IFC committed an unsecured A loan of US$40 million to Glenmark on February 12, 2021 through an allocation under the IFC COVID-19 response facility to fund the Company's ongoing capital expenditure program in India and proposed refinancing of foreign currency debt maturities (“Project”).

In June 2016, IFC had invested in convertible debt of US$75 million in Glenmark to finance the Company’s expansion project at the time, which has now been completed. The Project (2021 investment) is linked to Glenmark (#38371, 2016 investment): https://disclosures.ifc.org/project-detail/SII/38371/glenmark 

Associated Advisory Engagement

                                        

Sponsor / Cost / Location

Development Impact

E&S Category Rationale / Risks and Mitigation